𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Knock-down of amphiregulin inhibits cellular invasion in inflammatory breast cancer

✍ Scribed by Andrea Baillo; Craig Giroux; Stephen P. Ethier


Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
456 KB
Volume
226
Category
Article
ISSN
0021-9541

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

We have previously shown that SUM‐149 human breast cancer cells require an amphiregulin (AREG) autocrine loop for cell proliferation. We also demonstrated that AREG can increase epidermal growth factor receptor (EGFR) stability and promote EGFR localization to the plasma membrane. In the present studies we successfully knocked‐down AREG expression in SUM‐149 cells by lentiviral infection of AREG shRNA. In the absence of AREG expression, SUM‐149 cell growth was slowed, but not completely inhibited. Furthermore, cells infected with AREG shRNA constructs showed an increase in EGFR protein expression by Western blot. Immunofluorescence and confocal microscopy showed that following AREG knock‐down, EGFR continued to localize to the cell surface. Soft agar assays demonstrated that AREG knock‐down cells retain anchorage‐independent growth capacity. Additionally mammosphere forming assays and Adefluor staining analysis showed that knock‐down of AREG expression did not affect the expression of stem cell phenotypes. However, following AREG knock‐down, SUM‐149 cells demonstrated a dramatic decrease in their ability to invade a Matrigel matrix. Consistent with this observation, microarray analysis comparing cells infected with a non‐silencing vector to the AREG knock‐down cells, identified genes associated with the invasive phenotype such as RHOB and DKK1, and networks associated with cell motility such as integrin‐linked kinase signaling, and focal adhesion kinase signaling. AREG was also found to modulate WNT and Notch signaling in these cells. Thus, AREG functions in regulating the invasive phenotype, and we propose that this regulation may be through altered signaling that occurs when AREG activates plasma membrane localized EGFR. J. Cell. Physiol. 226: 2691–2701, 2011. © 2011 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


High ID2 protein expression correlates w
✍ Maria Stighall; Christina Manetopoulos; Håkan Axelson; Göran Landberg 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 419 KB

## Abstract ID proteins have been implicated in the regulation of cell proliferation and differentiation in various cell types during normal development as well as in the formation of cancer. Our aim was to delineate the expression of ID2 by immunohistochemistry in primary breast cancer in order to

Phenylbutyrate inhibits the invasive pro
✍ Erica S. Dyer; Michelle T. Paulsen; Sonja M. Markwart; Meidee Goh; Donna L. Liva 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 98 KB

## Abstract Histone deacetylase inhibitors, such as phenylbutyrate, are currently undergoing clinical trials as potential anticancer agents. Phenylbutyrate can induce cell differentiation and apoptosis in a number of cancer cell types and can act in synergy with ionizing radiation and chemotherapy

Expression of growth factors, growth-inh
✍ de Jong, Johannes S.; van Diest, Paul J.; van der Valk, Paul; Baak, Jan P. A. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 2 views

Growth factors may play an important role in tumour growth and angiogenesis by their influence on tumour cell proliferation or their effect on neovascularization. The aim of the present study was to determine which of the growth factors, growth-inhibiting factors, and their receptors investigated in

ChemInform Abstract: Efficient Synthesis
✍ Pijus K. Mandal; Eric M. Freiter; Allison L. Bagsby; Fredika M. Robertson; John 📂 Article 📅 2012 🏛 John Wiley and Sons ⚖ 33 KB 👁 1 views

## Abstract A highly efficient synthesis of the promising Cox‐2 inhibitor, apricoxib (VI), in only three steps from commercially available starting material is given.